Redcare Pharmacy 配当と自社株買い

配当金基準チェック /06

Redcare Pharmacy配当金を支払った記録がありません。

主要情報

n/a

配当利回り

-0.1%

バイバック利回り

総株主利回り	-0.1%
将来の配当利回り	0%
配当成長	n/a
次回配当支払日	n/a
配当落ち日	n/a
一株当たり配当金	n/a
配当性向	n/a

最近の配当と自社株買いの更新

更新なし

Recent updates

Is There An Opportunity With Redcare Pharmacy NV's (ETR:RDC) 48% Undervaluation?

Dec 06

Is Redcare Pharmacy (ETR:RDC) Using Too Much Debt?

Sep 07

Why Redcare Pharmacy NV (ETR:RDC) Could Be Worth Watching

Aug 02

Why We're Not Concerned About Redcare Pharmacy NV's (ETR:RDC) Share Price

Jul 17

Broker Revenue Forecasts For Shop Apotheke Europe N.V. (ETR:SAE) Are Surging Higher

May 28

Here's Why Shop Apotheke Europe (ETR:SAE) Can Afford Some Debt

May 11

We Think Shop Apotheke Europe (ETR:SAE) Has A Fair Chunk Of Debt

Jan 10

Is Shop Apotheke Europe (ETR:SAE) Using Too Much Debt?

Sep 25

Is Shop Apotheke Europe (ETR:SAE) Weighed On By Its Debt Load?

Jun 08

Is Shop Apotheke Europe (ETR:SAE) Using Too Much Debt?

Feb 28

Here's Why Shop Apotheke Europe (ETR:SAE) Has A Meaningful Debt Burden

Aug 01

Shop Apotheke Europe N.V.'s (ETR:SAE) About To Shift From Loss To Profit

May 11

Shop Apotheke Europe (ETR:SAE) Has A Somewhat Strained Balance Sheet

Apr 14

Insider Buying: The Shop Apotheke Europe N.V. (ETR:SAE) Chairman of the Managing Board & CEO Just Bought €96k Worth Of Shares

Mar 14

決済の安定と成長

配当データの取得

安定した配当: RDCの 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。

増加する配当: RDCの配当金が増加しているかどうかを判断するにはデータが不十分です。

配当利回り対市場

Redcare Pharmacy 配当利回り対市場

RDC 配当利回りは市場と比べてどうか？
セグメント	配当利回り
会社 (RDC)	n/a
市場下位25% (DE)	1.7%
市場トップ25% (DE)	4.8%
業界平均 (Consumer Retailing)	3.9%
アナリスト予想 (RDC) (最長3年)	0%

注目すべき配当: RDCは最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。

高配当: RDCは最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。

株主への利益配当

収益カバレッジ: RDCの配当性向を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。

株主配当金

キャッシュフローカバレッジ: RDCが配当金を報告していないため、配当金の持続可能性を計算できません。

Redcare Pharmacy 配当と自社株買い

配当金 基準チェック /06

主要情報

最近の配当と自社株買いの更新

Recent updates

Consensus EPS estimates fall by 33%

Redcare Pharmacy NV Revises Sales Guidance for the Full Year 2024

Second quarter 2024 earnings released

Redcare Pharmacy NV (XTRA:RDC) acquired MediService AG.

Forecast to breakeven in 2025

First quarter 2024 earnings released

Is There Now An Opportunity In Redcare Pharmacy NV (ETR:RDC)?

Are Investors Undervaluing Redcare Pharmacy NV (ETR:RDC) By 26%?

Investors Interested In Redcare Pharmacy NV's (ETR:RDC) Revenues

Redcare Pharmacy NV Announces Management Departures

New minor risk - Shareholder dilution

Forecast breakeven date moved forward to 2024

Redcare Pharmacy NV to Report Q3, 2024 Results on Nov 05, 2024

Full year 2023 earnings: EPS exceeds analyst expectations

Redcare Pharmacy NV, Annual General Meeting, Apr 17, 2024

Redcare Pharmacy (ETR:RDC) Is Carrying A Fair Bit Of Debt

Price target increased by 7.6% to €142

Consensus EPS estimates upgraded to €0.86 loss

Why Investors Shouldn't Be Surprised By Redcare Pharmacy NV's (ETR:RDC) P/S

Is There An Opportunity With Redcare Pharmacy NV's (ETR:RDC) 48% Undervaluation?

Forecast breakeven date moved forward to 2024

Consensus estimates of losses per share improve by 24%

Third quarter 2023 earnings released

Is Redcare Pharmacy (ETR:RDC) Using Too Much Debt?

Consensus EPS estimates upgraded to €1.43 loss

CFO & Member of Management Board recently sold €1.0m worth of stock

Consensus estimates of losses per share improve by 20%

New minor risk - Share price stability

Now 21% undervalued

Why Redcare Pharmacy NV (ETR:RDC) Could Be Worth Watching

Why We're Not Concerned About Redcare Pharmacy NV's (ETR:RDC) Share Price

Consensus EPS estimates fall by 16%

New minor risk - Profitability

Consensus EPS estimates upgraded to €1.64 loss

Price target increased by 8.1% to €101

Broker Revenue Forecasts For Shop Apotheke Europe N.V. (ETR:SAE) Are Surging Higher

Consensus revenue estimates increase by 19%

Price target increased by 7.5% to €99.08

Consensus EPS estimates fall by 15%

Consensus EPS estimates fall by 15%, revenue upgraded

Co-Founder recently sold €454k worth of stock

Here's Why Shop Apotheke Europe (ETR:SAE) Can Afford Some Debt

First quarter 2023 earnings released

Price target increased by 7.5% to €90.00

COO & Member of the Managing Board recently sold €331k worth of stock

Consensus EPS estimates upgraded to €2.36 loss, revenue downgraded

Full year 2022 earnings: EPS misses analyst expectations

No longer forecast to breakeven

COO & Member of the Managing Board recently sold €149k worth of stock

We Think Shop Apotheke Europe (ETR:SAE) Has A Fair Chunk Of Debt

Now 22% undervalued

Forecast to breakeven in 2025

Chairman of the Managing Board & CEO recently bought €85k worth of stock

Shop Apotheke Europe N.V. to Report Fiscal Year 2022 Results on Mar 07, 2023

Price target decreased to €91.64

Third quarter 2022 earnings released

Price target decreased to €98.79

Is Shop Apotheke Europe (ETR:SAE) Using Too Much Debt?

Co-Founder recently sold €972k worth of stock

Consensus forecasts updated

No longer forecast to breakeven

Second quarter 2022 earnings released

Shop Apotheke Europe N.V. Re-Confirms Earnings Guidance for 2022

COO & Member of the Managing Board recently sold €1.5m worth of stock

Co-Founder recently sold €953k worth of stock

Is Shop Apotheke Europe (ETR:SAE) Weighed On By Its Debt Load?

No longer forecast to breakeven

First quarter 2022 earnings: Revenues in line with analyst expectations

Consensus forecasts updated

No longer forecast to breakeven

Shop Apotheke Europe N.V. (XTRA:SAE) acquired FIRST A.

No longer forecast to breakeven

Co-Founder recently sold €916k worth of stock

Forecast breakeven date pushed back to 2024

Full year 2021 earnings: Revenues in line with analyst expectations

配当金基準チェック /06